History of the Daiichi Sankyo Group

Challenging to continue contributing to patients throughout a history of over 100 years

Daiichi Sankyo continues to take on the challenge of continuously creating innovative pharmaceuticals, leveraging our strengths in Science & Technology cultivated over more than 100 years of history. In our current 5-year Business Plan starting from 2021, we have clearly positioned "Global Pharma Innovator with Competitive Advantage in Oncology" as our 2025 Goal and have been accelerating our growth. Looking ahead, we aim to further contribute to the health and enrichment of people's lives around the world, with our 2030 Vision of becoming "Innovative Global Healthcare Company Contributing to the Sustainable Development of Society."

Our 5-year Business Plan

1st Term 3rd Term 5th Term Maximization of synergy and Promotion of measures toward Become a "Global Pharma expansion of growth foundation sustainable growth beyond LOE* Innovator with a competitive • Focus on thrombosis, cancer, diabetes · Focus on thrombosis, advantage in oncology," and · Maximize sales of Olmesartan franchises cardiovascular-metabolics, and cancer fields shift to further growth toward · Acquire Ranbaxy Laboratories and integrate it • Divest and liquidate Ranbaxy into the Group Return to innovative business our 2030 Vision * Loss of exclusivity 2007 2010 2016 2021 2013 2nd Term 4th Term

Transformation to become a
Global Pharma Innovator with a
competitive advantage in oncology

- Grow beyond LOE
- Establish a foundation of sustainable growth

2030 Vision

Innovative Global
Healthcare Company
Contributing to
the Sustainable Development
of Society

· Conduct frontline and back-end

business model

· Focus on thrombosis,

Advancement of global hybrid

cardiovascular-metabolics, and cancer fields

· Expand operating foundations in Japan